hcv drugs

[cure2015]

what is future of hcv treatment and cure
I know of sofosbuvir and simeprevir clinical trials
is there any other exciting new drug coming which will eradicate hcv?
the current triple therapy has a cure rate of 69-80 percent?

[cure2015]

Thank u so much
u r very kind

I'm trying to be strong as I live alone
Studyin while living alone when all this is going in your head makes one really tired
these clinical trials are keeping my hopes alive

there was one clinical trial with sofosbuvir and daclatesvir going on with cure rate of 99-100 %, but it was stopped after phase 2 by the companies without any health issues
any updates on that

[BoceprevirGal]

Sure, but I made a typo up above, I meant "the 12 week Treatment is Interferon free, and does include Ribavirin".....
   The Aviator Study has already ended, yielding promising news of a 12 week Treatment, (Interferon free, like I mentioned) with a 98% cure rate, for people whohaven never Treated, and it also looks promising for people who have tried other Treatments, and failed. I would have to review the Aviator Study info, to find you the exact % for that group.
    There is alink floating aroundhere, somewhere, which has a handy list of all the new med combos coming out, and it is very exciting.  I am just amazed at all the new medical break-throughs, there is even one study in which the treartment is just one shot, but it is only in "Phase 1"
   The ASviator Study drugs have been put on "fast-track" by the FDA,  which is why it should be comingout in 2014~  That is why my Hubs is in a "Phase 3" study of it, and the Aviator Study was a Phase 3. It's kinda complicated, but if you stickaround here, the info sinks in nicely~

[pooh55811]

There are many new drugs now in clinical trials. I am going to post some presentation titles and some very concise notes under each title. To view each study/trial results, go to Clinical Care Options, Register (you may have to say you are a doctor or nurse), and then you can read the full articles. They are free. You just have to register.

http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage.aspx

Clinical Care Options
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

HCV Phase III Studies and Approved Agents
In this downloadable slideset, Paul Y. Kwo, MD; David R. Nelson, MD; and Stefan Zeuzem, MD, review results from HCV phase III trials and key studies of approved HCV agents from the 2013 European Association for the Study of Liver.

CONCISE: Interim Results Show High SVR Rates With Either 12 or 24 Weeks of Telaprevir Plus Peginterferon/Ribavirin in Patients With HCV Genotype 1 and IL28B CC Genotype
Among patients who completed 12 weeks of triple therapy, 100% SVR12 rate among patients who continued to receive peginterferon/ribavirin through 24 weeks vs 89% SVR4 rate among patients who stopped all therapy at 12 weeks.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

QUEST-1: Simeprevir Plus PegIFN/RBV Significantly Improves SVR12 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV
Triple therapy was well tolerated and 85% of patients were able to shorten treatment to 24 weeks, of whom 91% achieved SVR12.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

POSITRON: Sofosbuvir/Ribavirin Superior to Placebo With 78% SVR12 Rate in Genotype 2/3 HCV–Infected Patients Intolerant of, Ineligible for, or Unwilling to Receive IFN
Sofosbuvir plus ribavirin is a safe, effective, IFN-free alternative for patients chronically infected with genotype 2/3 HCV who have no other treatment options available.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

QUEST-2: Simeprevir Plus PegIFN/RBV Superior to PegIFN/RBV for SVR12 in Treatment-Naive Patients With Genotype 1 HCV
Triple therapy was well tolerated and enabled most patients (91%) to shorten the duration of therapy to 24 weeks while maintaining a high SVR12 rate of 86% in this subgroup.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

NEUTRINO: Sofosbuvir Plus Peginterferon/Ribavirin Achieves High SVR12 Rate, Well Tolerated in Treatment-Naive Patients With Genotype 1, 4, 5, or 6 HCV
The triple-therapy regimen yielded 90% SVR12 in the overall population, and all patient subgroups attained at least 80% SVR12 rate, including patients with cirrhosis and those with IL28B non-CC genotype.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

FISSION: Sofosbuvir/Ribavirin Noninferior to Peginterferon/Ribavirin for SVR12 in Treatment-Naive Patients With HCV Genotype 2/3
Efficacy was similar between the 2 treatment arms, but sofosbuvir/ribavirin demonstrated superior safety and tolerability with shorter therapy compared with peginterferon/ribavirin.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

FUSION: Sofosbuvir/Ribavirin Superior to Historical Controls for SVR12 in Treatment-Experienced Patients With Genotype 2/3 HCV
Significantly better rates of SVR12 with both 12 and 16 weeks of therapy compared with historical controls, with better outcomes with 16 weeks of therapy among patients with genotype 3 HCV
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

STARTVerso1: Faldaprevir Plus Peginterferon/Ribavirin Highly Effective, Well Tolerated in Treatment-Naive Patients Infected With Genotype 1 HCV
Most patients receiving faldaprevir (88%) were able to shorten therapy to 24 weeks total, without compromising sustained virologic response, which was 88% in this subgroup.

Additional Highlights of HCV Investigational Agents and HBV
In this downloadable slideset, Jordan J. Feld, MD, MPH; Graham R. Foster, FRCP, PhD; and Norah Terrault, MD, MPH, review the results from early-phase studies for both HCV and HBV therapeutic agents presented at the 2013 European Association for the Study of Liver.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

MK-5172 Plus PegIFN/RBV Achieves 86% to 92% SVR24 Rates in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV
91% of patients receiving MK-5172 100 mg/day were eligible for shortened (24-week) duration of therapy, of whom 90% achieved SVR24.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

High SVR12 Rates With Short-Course (6 or 12 Weeks) of Ledipasvir and GS-9451 Plus PegIFN/RBV Quadruple Therapy in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV Infection and IL28B CC Genotype
92% of patients achieved early virologic response and were eligible for short-course therapy; SVR12 rates were 98% with 12 weeks vs 79% with 6 weeks of quadruple therapy.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Vaniprevir Plus PegIFN/RBV Significantly Increases SVR24 Rate vs PegIFN/RBV Retreatment in Cirrhotic, Genotype 1 HCV–Infected, Previous Nonresponders to PegIFN/RBV
Vaniprevir-based therapy generally well tolerated, with increased incidence of mild to moderate gastrointestinal adverse events.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Daclatasvir Plus Asunaprevir Plus BMS-791325 Achieves ≥ 88% SVR Rates in Noncirrhotic Treatment-Naive Patients With Genotype 1 HCV
The all-oral regimen combining an NS5a inhibitor, a protease inhibitor, and a nonnucleoside polymerase inhibitor was well tolerated at both doses of BMS-791325 studied.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

HBV DNA Seroclearance Significantly Reduces Risk of HCC in Patients With High Baseline Viral Loads
Seroclearance of HBeAg, HBsAg did not significantly decrease HCC risk in adjusted analysis.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

COMMAND: Daclatasvir Plus PegIFN/RBV Improves SVR24 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 2/3 HCV
The triple-drug regimen allowed 83% of patients to receive shorter treatment durations of only 12 or 16 weeks, and safety and tolerability was comparable to pegIFN/RBV alone.
Source: 2013 Annual Meeting of the European Association for the Study of the Liver

[cure2015]

Thanks for ur reply
How long wll the aviator study last?
So, in the next few years, we humans will have 2 - 3 classes of drugs at our disposal

[orphanedhawk]

The future is bright for hcv treatment. Nobody knows when they will be approved for general usage. Hopefully not too long~

[BoceprevirGal]

  Yes, there is another new Treatment expected to come out in 2014, which my husband is in a Phase 3 Trial of,  the meds are from Abtvie. I'm not so great at posting links correctly, but you can easily look up the info by putting "Aviator Study" into your search engine.
  The 12 week treatment is Interferon free, and does include Interferon, and two other PA's...the PA's just have #'s right now, called Abt-333 and, Abt-450/Ritonavir(not a protease inhibitor, but an anti-viral, also used with HIV Tx)/Abt 267.
   Now, since these meds are still in the study phase, I'm not sure what the final regime will be, I only listed it, the way my Hubs is taking it.  That's why you should also read the Aviator Study :)